发布求助
文献互助 智能选刊 最新文献

Cancer Radiotherapie最新文献

筛选
英文 中文
Personalized strategies for brachytherapy of cervix cancer 宫颈癌近距离放射治疗的个性化策略。
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-11-01 DOI: 10.1016/j.canrad.2024.09.006
Guillaume Camprodon , Alexandra Gabro , Zineb El Ayachi , Supriya Chopra , Remi Nout , Philippe Maingon , Cyrus Chargari
{"title":"Personalized strategies for brachytherapy of cervix cancer","authors":"Guillaume Camprodon ,&nbsp;Alexandra Gabro ,&nbsp;Zineb El Ayachi ,&nbsp;Supriya Chopra ,&nbsp;Remi Nout ,&nbsp;Philippe Maingon ,&nbsp;Cyrus Chargari","doi":"10.1016/j.canrad.2024.09.006","DOIUrl":"10.1016/j.canrad.2024.09.006","url":null,"abstract":"<div><div>Among most tailored approaches in radiation oncology, the development of brachytherapy for the treatment of cervical cancer patients has benefited from various technological innovations. The development of 3D image-guided treatments was the first step for treatment personalization. This breakthrough preceded practice homogenization and validation of predictive dose and volume parameters and prognostic factors. We review some of the most significant strategies that emerged from the ongoing research in order to increase personalization in uterovaginal brachytherapy. A better stratification based on patients and tumors characteristics may lead to better discriminate candidates for intensification or de-escalation strategies, in order to still improve patient outcome while minimizing the risk of treatment-related side effects.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 6","pages":"Pages 610-617"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reirradiation of bone metastasis: A narrative review of the literature 骨转移瘤的再照射：文献综述
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-11-01 DOI: 10.1016/j.canrad.2024.07.009
Emma Agnoux , William Gehin , Anaïs Stefani , Vincent Marchesi , Nicolas Martz , Jean-Christophe Faivre
{"title":"Reirradiation of bone metastasis: A narrative review of the literature","authors":"Emma Agnoux ,&nbsp;William Gehin ,&nbsp;Anaïs Stefani ,&nbsp;Vincent Marchesi ,&nbsp;Nicolas Martz ,&nbsp;Jean-Christophe Faivre","doi":"10.1016/j.canrad.2024.07.009","DOIUrl":"10.1016/j.canrad.2024.07.009","url":null,"abstract":"<div><div>Patients with bone metastasis are prevalent among those receiving palliative radiotherapy (RT), with approximately 20 % requiring reirradiation (reirradiation). The goal of bone reirradiation may be local control (oligoreoccurrence or oligoprogression of a previously treated lesion or in a previous treatment field) or symptomatic (threatening or painful progression). Published data on bone reirradiation indicate almost two-thirds of overall pain response. The primary organ at risk (especially for spine treatment) is the spinal cord. The risk of radiation myelitis is<!--> <!-->&lt;<!--> <!-->1 % for cumulative doses of<!--> <!-->&lt;<!--> <!-->50<!--> <!-->Gy. Intensity-modulated RT (IMRT) and stereotactic RT (SRT) appear to be safer than three-dimensional RT (3DRT), although randomized trials comparing these techniques in reirradiation are lacking. Reirradiation requires multidisciplinary assessment. Alternative treatments for bone metastases (surgery, interventional radiology, etc.) must be considered. Patients should have a performance status<!--> <!-->≤<!--> <!-->2, with at least a 1-month interval between treatments. The planning process involves reviewing previous RT plans, cautious dose adjustments, and precise target delineation and dose distribution to minimize toxicity. Cumulative dosimetry, patient consent, and vigilant post-treatment monitoring and dose reporting are crucial.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 6","pages":"Pages 568-575"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reirradiation of squamous cell carcinoma of the head and neck with external photons: A practical review of the literature 使用外部光子对头颈部鳞状细胞癌进行再照射：文献综述。
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-11-01 DOI: 10.1016/j.canrad.2024.07.011
Élodie Queyrel , Arianne Lapierre , Yoann Pointreau , Michel Lapeyre , Julian Biau , Amandine Ruffier
{"title":"Reirradiation of squamous cell carcinoma of the head and neck with external photons: A practical review of the literature","authors":"Élodie Queyrel ,&nbsp;Arianne Lapierre ,&nbsp;Yoann Pointreau ,&nbsp;Michel Lapeyre ,&nbsp;Julian Biau ,&nbsp;Amandine Ruffier","doi":"10.1016/j.canrad.2024.07.011","DOIUrl":"10.1016/j.canrad.2024.07.011","url":null,"abstract":"<div><div>The modalities of management by reirradiation for recurrence or a second localization of head and neck squamous cell carcinoma (HNSCC) in previously irradiated terrain is challenging due to the great heterogeneity of data in the literature, mainly retrospective data reporting non-negligible risks of serious late toxicity events. With the recent development of more precise and conformal radiotherapy techniques such as intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic radiotherapy (SBRT), the benefit-to-risk ratio of reirradiation has evolved in recent years with encouraging results, but patient selection is crucial. The aim of this review is to discuss the role of HNSCC reirradiation in terms of patient selection and external photon radiotherapy techniques for definitive tumor reirradiation and postoperative reirradiation.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 6","pages":"Pages 580-585"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain metastases reirradiation 脑转移瘤再放射。
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-11-01 DOI: 10.1016/j.canrad.2024.09.005
Claire Petit , Agnès Tallet
{"title":"Brain metastases reirradiation","authors":"Claire Petit ,&nbsp;Agnès Tallet","doi":"10.1016/j.canrad.2024.09.005","DOIUrl":"10.1016/j.canrad.2024.09.005","url":null,"abstract":"<div><div>The advances in cancer screening and therapies have allowed the improvement of metastatic patients’ survival, including those with brain metastases. This led to a substantial shift in brain metastases patients’ management for whom whole-brain radiation therapy, formerly widely used, has given way to a more focused management in which single- or multifractionated stereotactic radiation therapy now plays a predominant role. Although stereotactic radiation therapy offers excellent local control rates (70 to 90%), it does not prevent brain recurrence outside the radiation field, which is all the more frequent the higher the number of initial metastases and the longer the patient's survival. In the case of brain recurrence after irradiation, therapeutic options will depend both on the previous treatment and on the features of the recurrence. This article aims to review the available data on the efficacy and tolerability of various reirradiation schemes in different clinical situations.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 6","pages":"Pages 538-546"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thoracic reirradiation of recurrent non-small cell lung carcinoma: A comprehensive review 复发性非小细胞肺癌的胸部再照射：全面回顾。
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-11-01 DOI: 10.1016/j.canrad.2024.08.004
Louis Grasso , Vincent Bourbonne , Francois Lucia
{"title":"Thoracic reirradiation of recurrent non-small cell lung carcinoma: A comprehensive review","authors":"Louis Grasso ,&nbsp;Vincent Bourbonne ,&nbsp;Francois Lucia","doi":"10.1016/j.canrad.2024.08.004","DOIUrl":"10.1016/j.canrad.2024.08.004","url":null,"abstract":"<div><div>Due to the recent advances in the systemic treatment of non-small cell lung cancer, the management of locoregional recurrences, especially after initial radiotherapy (with or without concurrent chemotherapy), is of increasing significance. The potential alternatives in this setting include: a salvage local strategy (based on surgery, radiotherapy or thermoablative treatment), promising approach, but sometimes difficult to implement in often frail patients, and whose modalities remain under-researched; or alternatively, the initiation of systemic treatment, where the prognosis aligns with that of de novo metastatic patients. This comprehensive literature review focused on salvage radiotherapy treatment of recurrent non-small cell lung carcinomas, after initial radiotherapy, with or without associated systemic treatment. It aims to present the main findings on this area, from patient selection and preparation, to key characteristics, including dosimetric aspects, and the main limitations and uncertainties associated with this therapeutic modality.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 6","pages":"Pages 591-596"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Committee of the new positions of the Société française de radiothérapie oncologique: Toward an advanced practice master in radiotherapy 法国肿瘤放射治疗学会新职位委员会：争取成为放射治疗高级实践硕士。
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-11-01 DOI: 10.1016/j.canrad.2024.07.005
Sophie Boisbouvier , Simon Corbin , Axel Béasse , Aurélien De Oliveira , Céline Bourgier , behalf of the Comité des manipulateurs d’électroradiologie médicale en radiothérapie de l’AFPPE
{"title":"Committee of the new positions of the Société française de radiothérapie oncologique: Toward an advanced practice master in radiotherapy","authors":"Sophie Boisbouvier ,&nbsp;Simon Corbin ,&nbsp;Axel Béasse ,&nbsp;Aurélien De Oliveira ,&nbsp;Céline Bourgier ,&nbsp;behalf of the Comité des manipulateurs d’électroradiologie médicale en radiothérapie de l’AFPPE","doi":"10.1016/j.canrad.2024.07.005","DOIUrl":"10.1016/j.canrad.2024.07.005","url":null,"abstract":"<div><div>In 2022, the radiation therapist committee of the Association française du personnel paramédical d’electroradiologie médicale (AFPPE, French association of paramedical electroradiology technicians), the Société française de radiothérapie oncologique (SFRO, French society of radiation oncology) and the Syndicat national des radiothérapeutes oncologue (SNRO, national syndicate of radiation oncologists) have been committed to working on the development of advanced practice roles. The objective of this article is to report the activities that should be in the scope of radiation therapists advanced practice and describe the competences required for these activities. This work was carried out by six radiation therapists, six radiation oncologists and one medical physicist representatives of the French national societies for each professional group. First, a basic list of activities was established and then competences were identified for groups of activities. In total, the list includes five core competences, nine competences and nine groups of activities that can be divided into the four pillars of advanced practice. The nine groups of activities can be presented in seven different dimensions including patient care and support, treatment planning, treatment imaging and delivery, management and consultancy, quality and risk management, research and innovation, education and training. The French advanced practice competences framework was developed with a multidisciplinary group to move forward the project of a master degree in advanced practice in radiation therapy in France.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 6","pages":"Pages 560-564"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
News and prospects on radiotherapy for bladder cancer: Is trimodal therapy becoming the gold standard? 膀胱癌放射治疗的新闻和前景：三联疗法是否正在成为金标准？
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-11-01 DOI: 10.1016/j.canrad.2024.08.005
Olivier Riou , Christophe Hennequin , Jonathan Khalifa , Paul Sargos
{"title":"News and prospects on radiotherapy for bladder cancer: Is trimodal therapy becoming the gold standard?","authors":"Olivier Riou ,&nbsp;Christophe Hennequin ,&nbsp;Jonathan Khalifa ,&nbsp;Paul Sargos","doi":"10.1016/j.canrad.2024.08.005","DOIUrl":"10.1016/j.canrad.2024.08.005","url":null,"abstract":"<div><div>Trimodal therapy consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy, has emerged as a valuable therapeutic alternative to radical cystectomy in patients with muscle invasive bladder cancer. Concomitant radiosensitising chemotherapy is a component of trimodality increasing locoregional control compared to radiotherapy alone. The combinations 5-fluorouracil with mitomycin or cisplatin are the best supported in the literature. Gemcitabine appears to be a feasible and promising alternative. There is considerable international heterogeneity in terms of dose, volumes and fractionation. The most commonly used regimens are moderately hypofractionated (55<!--> <!-->Gy in 20 fractions over 4 weeks) and normofractionated (64<!--> <!-->Gy in 32 fractions) regimens. Radiotherapy for bladder cancer is an effective and evolving treatment, with current technical developments, and studies of new combinations with systemic treatments underway.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 6","pages":"Pages 623-627"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of nanoparticles in radiation oncology 纳米粒子在放射肿瘤学中的应用。
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-11-01 DOI: 10.1016/j.canrad.2024.08.006
Ulrike Schick , Vincent Bourbonne , François Lucia , Camille Verry
{"title":"Use of nanoparticles in radiation oncology","authors":"Ulrike Schick ,&nbsp;Vincent Bourbonne ,&nbsp;François Lucia ,&nbsp;Camille Verry","doi":"10.1016/j.canrad.2024.08.006","DOIUrl":"10.1016/j.canrad.2024.08.006","url":null,"abstract":"<div><div>Radiotherapy is a major therapeutic strategy for cancer treatment. Despite many technology advances in the last two decades, local control remains often suboptimal, especially in locally advanced tumours, which are often hypoxic, and radioresistant. In addition, irradiation of surrounding tissues and organs at risk usually precludes further dose escalation to minimize acute and late toxicities. Radiosensitizing agents such as chemotherapies targeting the DNA repair, or targeted monoclonal antibodies (cetuximab) have been shown to improve local control in many tumour types. More recently, radioenhancers have emerged as a new way to overcome the limitations of radiation. Here, we review the state of the art in this field and will focus on the past and ongoing clinical trials with the nanoparticles NBTXR3 and AGuIX®.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 6","pages":"Pages 618-622"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation-induced lymphocyte apoptosis assay: Primetime for routine clinical use? 辐射诱导淋巴细胞凋亡测定：常规临床应用的黄金时期？
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-10-01 DOI: 10.1016/j.canrad.2024.06.002
David Azria , Morgan Michalet , Olivier Riou , Céline Bourgier , Muriel Brengues , Yohann Sroussi , Sophie Gourgou , Marie-Pierre Farcy-Jacquet , Léa Kotzki , Mahmut Ozsahin
{"title":"Radiation-induced lymphocyte apoptosis assay: Primetime for routine clinical use?","authors":"David Azria ,&nbsp;Morgan Michalet ,&nbsp;Olivier Riou ,&nbsp;Céline Bourgier ,&nbsp;Muriel Brengues ,&nbsp;Yohann Sroussi ,&nbsp;Sophie Gourgou ,&nbsp;Marie-Pierre Farcy-Jacquet ,&nbsp;Léa Kotzki ,&nbsp;Mahmut Ozsahin","doi":"10.1016/j.canrad.2024.06.002","DOIUrl":"10.1016/j.canrad.2024.06.002","url":null,"abstract":"<div><div>The impact of curative radiotherapy mainly depends on the total dose delivered to the tumor. However, despite recent technological advances, the dose delivered to surrounding healthy tissues may reduce the therapeutic ratio of many radiation treatments. In the same population treated at one center with the same technique, individual radiosensitivity clearly exists, particularly in terms of late side effects that are, in principle, non-reversible. This article details the history of the radiation-induced lymphocyte apoptosis assay, from preclinical data to multicenter clinical trials. It puts the performance of such assays into perspective to define the optimal clinical situations for its use in daily practice.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 5","pages":"Pages 442-448"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards clinical application of ultra-high dose rate radiotherapy and the FLASH effect: Challenges and current status 超高剂量率放射治疗和FLASH效应的临床应用：挑战与现状。
IF 1.5 4区 医学
Cancer Radiotherapie Pub Date : 2024-10-01 DOI: 10.1016/j.canrad.2024.07.001
Abdulhamid Chaikh , Magali Édouard , Christelle Huet , Fabien Milliat , Carmen Villagrasa , Aurélie Isambert
{"title":"Towards clinical application of ultra-high dose rate radiotherapy and the FLASH effect: Challenges and current status","authors":"Abdulhamid Chaikh ,&nbsp;Magali Édouard ,&nbsp;Christelle Huet ,&nbsp;Fabien Milliat ,&nbsp;Carmen Villagrasa ,&nbsp;Aurélie Isambert","doi":"10.1016/j.canrad.2024.07.001","DOIUrl":"10.1016/j.canrad.2024.07.001","url":null,"abstract":"<div><div>Ultra-high dose rate external beam radiotherapy (UHDR-RT) uses dose rates of several tens to thousands of Gy/s, compared with the dose rate of the order of a few Gy/min for conventional radiotherapy techniques, currently used in clinical practice. The use of such dose rate is likely to improve the therapeutic index by obtaining a radiobiological effect, known as the “FLASH” effect. This would maintain tumor control while enhancing tissues protection. To date, this effect has been achieved using beams of electrons, photons, protons, and heavy ions. However, the conditions required to achieve this “FLASH” effect are not well defined, and raise several questions, particularly with regard to the definition of the prescription, including dose fractionation, irradiated volume and the temporal structure of the pulsed beam. In addition, the dose delivered over a very short period induces technical challenges, particularly in terms of detectors, which must be mastered to guarantee safe clinical implementation. IRSN has carried out an in-depth literature review of the UHDR-RT technique, covering various aspects relating to patient radiation protection: the radiobiological mechanisms associated with the FLASH effect, the used temporal structure of the UHDR beams, accelerators and dose control, the properties of detectors to be used with UHDR beams, planning, clinical implementation, and clinical studies already carried out or in progress.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"28 5","pages":"Pages 463-473"},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信